JP5216072B2 - 神経細胞特異的な逆行性輸送ベクター - Google Patents

神経細胞特異的な逆行性輸送ベクター Download PDF

Info

Publication number
JP5216072B2
JP5216072B2 JP2010263148A JP2010263148A JP5216072B2 JP 5216072 B2 JP5216072 B2 JP 5216072B2 JP 2010263148 A JP2010263148 A JP 2010263148A JP 2010263148 A JP2010263148 A JP 2010263148A JP 5216072 B2 JP5216072 B2 JP 5216072B2
Authority
JP
Japan
Prior art keywords
gene
vector
kit
envelope
vsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010263148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012110290A5 (enExample
JP2012110290A (ja
Inventor
和人 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, National Institute of Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Priority to JP2010263148A priority Critical patent/JP5216072B2/ja
Priority to PCT/JP2011/077142 priority patent/WO2012070639A1/ja
Priority to US13/988,973 priority patent/US9006411B2/en
Priority to EP11843579.1A priority patent/EP2644697B1/en
Publication of JP2012110290A publication Critical patent/JP2012110290A/ja
Publication of JP2012110290A5 publication Critical patent/JP2012110290A5/ja
Application granted granted Critical
Publication of JP5216072B2 publication Critical patent/JP5216072B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010263148A 2010-11-26 2010-11-26 神経細胞特異的な逆行性輸送ベクター Expired - Fee Related JP5216072B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2010263148A JP5216072B2 (ja) 2010-11-26 2010-11-26 神経細胞特異的な逆行性輸送ベクター
PCT/JP2011/077142 WO2012070639A1 (ja) 2010-11-26 2011-11-25 神経細胞特異的な逆行性輸送ベクター
US13/988,973 US9006411B2 (en) 2010-11-26 2011-11-25 Neuron-specific retrograde transport vector
EP11843579.1A EP2644697B1 (en) 2010-11-26 2011-11-25 Neuron-specific retrograde transport vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010263148A JP5216072B2 (ja) 2010-11-26 2010-11-26 神経細胞特異的な逆行性輸送ベクター

Publications (3)

Publication Number Publication Date
JP2012110290A JP2012110290A (ja) 2012-06-14
JP2012110290A5 JP2012110290A5 (enExample) 2012-08-23
JP5216072B2 true JP5216072B2 (ja) 2013-06-19

Family

ID=46145976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010263148A Expired - Fee Related JP5216072B2 (ja) 2010-11-26 2010-11-26 神経細胞特異的な逆行性輸送ベクター

Country Status (4)

Country Link
US (1) US9006411B2 (enExample)
EP (1) EP2644697B1 (enExample)
JP (1) JP5216072B2 (enExample)
WO (1) WO2012070639A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3266895A1 (en) * 2022-09-12 2024-03-21 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITION AND METHOD OF UNIVERSAL PSEUDOTYPE RETROVIRUSES
CN117867029B (zh) * 2023-12-29 2024-12-20 复百澳(苏州)生物医药科技有限公司 一种狂犬亚型假病毒的制备方法及应用
CN119639818A (zh) * 2025-02-18 2025-03-18 南京市计量监督检测院 一种假病毒颗粒的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124146A1 (en) 2000-01-28 2003-07-03 Schnell Matthias J. Recombinant Rhabdoviruses as live-viral vaccines
JP2004517057A (ja) * 2000-11-03 2004-06-10 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム
JP2009034029A (ja) * 2007-08-01 2009-02-19 Japan Science & Technology Agency 逆行性輸送能を有するウィルスベクター系
JP5123922B2 (ja) * 2009-12-02 2013-01-23 独立行政法人科学技術振興機構 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系

Also Published As

Publication number Publication date
US9006411B2 (en) 2015-04-14
WO2012070639A1 (ja) 2012-05-31
US20130315872A1 (en) 2013-11-28
EP2644697A1 (en) 2013-10-02
EP2644697B1 (en) 2018-12-26
JP2012110290A (ja) 2012-06-14
EP2644697A4 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
JP5123922B2 (ja) 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系
Kato et al. Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein
Mazarakis et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery
Desmaris et al. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins
Cronin et al. Altering the tropism of lentiviral vectors through pseudotyping
Watson et al. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins
ES2997865T3 (en) Adapter-based retroviral vector system for the selective transduction of target cells
Escors et al. Lentiviral vectors in gene therapy: their current status and future potential
Carpentier et al. Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein
JP2008503230A (ja) 非組み込み型且つ非複製型組換えレンチウイルス、その調製および使用
US10596264B2 (en) Peptides with viral infection enhancing properties and their use
JP2008303215A (ja) ベクターシステム
Kobayashi et al. Altering entry site preference of lentiviral vectors into neuronal cells by pseudotyping with envelope glycoproteins
Loewen et al. Lentiviral vectors
US9006411B2 (en) Neuron-specific retrograde transport vector
Coroadinha Cancer gene therapy: development and production of lentiviral vectors for gene therapy
JP2009034029A (ja) 逆行性輸送能を有するウィルスベクター系
US7749973B2 (en) Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors
Liehl et al. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain
Trabalza et al. Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins
Molina et al. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct
US20090233988A1 (en) Therapeutic Agents for Diseases Associated With Apoptotic Degeneration in Ocular Tissue Cells That Use SIV-PEDF Vectors
US20020168760A1 (en) Retroviral vectors for gene transfer into neuronal cells
JP2012110290A5 (enExample)
Kato et al. Highly efficient retrograde gene transfer for genetic treatment of neurological diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120705

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120705

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130301

R150 Certificate of patent or registration of utility model

Ref document number: 5216072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160308

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees